Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ricin toxin A chain is the protein subunit of ricin, a highly potent plant-derived toxin from Ricinus communis (castor bean plant)[3][5]. As part of a heterodimeric holotoxin (linked to the B chain via disulfide bond), the A chain is an N-glycoside hydrolase enzyme (approx. 32 kDa, 267 amino acids) that specifically depurinates adenine-4324 in the sarcin-ricin loop of eukaryotic 28S rRNA. This enzymatic lesion irreversibly blocks ribosomal function, thereby halting protein synthesis and rapidly killing affected cells[1][3][5][6]. Ricin toxin A chain is thus both a classic and highly effective ribosome-inactivating protein, responsible for the extreme toxicity of ricin holotoxin. There is significant interest in RTA as a biological warfare/terror agent, as well as a model for developing specific inhibitors and antidotes due to its unique mechanism of action[1][3][5][6].
Inhibition of the N-glycosidase activity (hydrolysis of adenine in 28S rRNA)[2][4][6]. Small molecule inhibitors bind to the active site, impeding access to substrate rRNA[4][6]. Antibodies neutralize and block uptake or enzymatic activity.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ricin toxin A chain (RTA).